We have demonstrated that adenosine enhances insulin-stimulated myocardial glucose uptake in situ. In the present study we determined the role of adrenergic influences and myocardial work on insulin-stimulated myocardial glucose uptake while varying intracoronary adenosine concentrations. Under pentobarbital anesthesia we instrumented mongrel dogs to obtain blood pressure, heart rate, and arterial and coronary sinus blood samples for measuring oxygen and glucose concentrations. An electromagnetic blood flow probe around the circumflex coronary artery allowed determinations of blood flow, and calculation of myocardial oxygen (MVO,) and glucose (MGU) uptakes. Somatostatin was infused i.v. (0.8 pg/kg . min-'1 along with 10 mu/kg. min-' regular insulin, and variable quantities of glucose to maintain euglycemia. Adenosine was infused at logarithmic incremental rates (0, 0.01, 0.1, 1.0, and 10 pmoles . min-') for 30 min each into the main left coronary arteries. Adrenergic blockade was achieved with i.v. propranolol (70 pg/kg bolus followed by 5 yg/kg mm 1 -' infusion), and phentolamine (95 pg/kg bolus followed by 9.5 pg/kg min-' infusion). Insulin infusion significantly increased MGU. Adenosine increased the maximal value for insulin-stimulated glucose uptake. Adrenergic blockade alone did not alter insulin-stimulated MGU, but reduced heart rate and MVO,. When evaluated relative to MVO, 1.0 pmoles/ml adenosine infusion increased MGU independent of work-related changes in the presence or absence of adrenergic blockade. With an adenosine infusion rate of 10 pmoles/ml myocardial glucose uptake returned to baseline. These data also support our earlier speculation that the MGU response to adenosine may be biphasic. These results suggest that antagonism of adrenergic effects by adenosine cannot account for adenosine's ability to enhance insulin's effects on glucose uptake in the heart, but that work-related influences should be accounted for in interpreting results of this kind.
Introduction
It has been proposed that adenosine may play an important role in myocardial function during physiological and pathophysiological states, owing to its vasoactive, inotropic, and dromotropic effects [l-5] . Much study has also been devoted to the effect of adenosine on tissue responsiveness to insulin. In adipose tissue adenosine has been shown to potentiate insulin's ability to stimulate glucose uptake [6-81, yet it decreases sensitivity of skeletal muscle to insulin [9, 10] . Recently, our work has focused on the effect of adenosine on in situ myocardial responsiveness to insulin. We have reported that adenosine, in a dose dependent fashion, potentiates insulin's ability to increase myocardial glucose uptake [ 11 , I 21, indicating that the response to adenosine in cardiac tissue is more akin to the adipose response than that of skeletal muscle. In one study, we infused somatostatin (SRIF) to reduce endogenous insulin below the level of detection [12] . Under those conditions adenosine did not alter basal (non-insulinstimulated) myocardial glucose uptake. When endogenous insulin was replaced with insulin infusions, adenosine potentiated the effects of insulin on glucose uptake [12] .
These data indicated that the presence of insulin can influence this metabolic effect of adenosine in the heart. A potential mechanism by which adenosine affects insulin-stimulated glucose uptake in the heart is via inhibition of the effect of catecholamines on insulin-stimulated glucose uptake. In a variety of tissues, adenosine has been shown to antagonize the inhibitory effects of adrenergic agents on insulin [13-151, thereby indirectly increasing insulin-stimulated glucose uptake. Although James et al. [16] reported that catecholamines alone can stimulate glucose uptake, they found that epinephrine inhibited the actions of insulin on glucose uptake in skeletal muscle, diaphragm, and myocardial tissues. In adipose tissue isoproterenol has been reported to have a biphasic effect on insulin-stimulated glucose uptake [ 131, wherein lower concentrations potentiate and higher concentrations inhibit insulin-stimulated glucose uptake [ 15-171. Part of these effects of catecholamines on insulin-stimulated glucose uptake in adipose tissue involve adenosine [ 15. 16, 18] . The reported stimulatory action of low concentrations of isoproterenol are abolished in the presence of adenosine deaminase; adipose tissue thus treated exhibits only inhibition of insulin-stimulated glucose uptake by isoproterenol [15, 17] . Similarly, Green [lS] reported that while isoproterenol, epinephrine, or norepinephrine alone had no effect on insulin-stimulated glucose uptake in adipocytes, all three adrenergic agonists had an inhibitory effect on this parameter in the presence of adenosine deaminase. Shanahan et al. [14] , in studying the interaction between isoproterenol and insulin in cardiac myocytes, found that isoproterenol reduced insulin-stimulated glucose uptake. When adenosine deaminase was added to the incubation medium along with isoproterenol and insulin, myocyte glucose uptake was further reduced. They interpreted this as indicating that adenosine, produced by the cells into the medium, antagonized isoproterenol's inhibitory effect on insulin; in the absence of adenosine, isoproterenol was able to fully express its inhibition of insulin's effects.
These early studies suggested that adenosine can enhance insulin-stimulated glucose uptake by antagonizing insulin-inhibitory adrenergic activity in adipose and myocardial tissue. With this in mind we hypothesized that (1) basal myocardial adrenergic activity in situ limits insulinstimulated glucose uptake, and (21 adenosine may thus enhance insulin-stimulated glucose uptake by actually antagonizing inhibitory actions of endogenous adrenergic activity. Through the use of adrenergic blockade in the same model as used previously [12] we determined if adenosine potentiation of insulin-stimulated glucose uptake is a result of adenosine's antagonism of adrenergic activity.
In isolated perfused hearts other laboratories have reported stimulation by, inhibition by. or no effect of adenosine on myocardial glucose metabolism [ 19-231. It has been suggested that these varied results are due to differences in work conditions, adenosine concentrations, and/or perfusate substrate profiles [ 12, 20, 22] . To address these concerns we examined our data relative to myocardial work, and over a range of adenosine infusion rates. Performing these experiments in an in situ blood perfused preparation ensured that physiological substrate profiles were used.
Methods
Twelve conditioned mongrel dogs of either sex, weighing 20-25 kg, were used in this study. Dogs were anesthetized with pentobarbital sodium (35 mg/kg i.v.>, intubated, and ventilated with room air against 3-5 cm HZ0 positive end-expiratory pressure using a Harvard respirator. Supplemental doses of pentobarbital were given as needed to maintain a surgical plane of anesthesia throughout the experimental protocol. Succinylcholine was given (1 mg/kg, iv.) to induce transient muscle relaxation, and a left thoracotomy was performed in the fifth intercostal space, the pericardium opened, and the heart exposed. A silastic catheter was placed into the coronary sinus via the right atria1 appendage and used to obtain coronary venous blood samples. A Gould electromagnetic flow probe was placed around the circumflex artery to measure blood flow with a Gould SP 2202 flowmeter. Angiocatheters (24-gauge) were inserted, one anterograde into the circumflex artery, the other retrograde into the left anterior descending coronary artery, for infusion of 0.9% saline, or various concentrations of adenosine, at a rate of 1 ml/min each. Patency of both vessels were maintained and blood flows were not affected by placement of the angiocatheters [11, 12, 24] .
A femoral arterial catheter was advanced into the abdominal aorta to measure arterial blood pressure, heart rate, and obtain arterial blood samples. Two catheters were placed into a femoral vein. One of these was used to infuse insulin, adrenergic blocking agents, and somatostatin. Glucose was infused as needed (see below) through the other femoral venous catheter. On-line hemodynamic measurements were recorded on a Gould 2800s Physiological Recorder. Arterial (A) and coronary sinus (CS) samples were collected anaerobically and assayed for glucose and oxygen content. Glucose concentrations were determined with a Yellow Springs 23A glucose analyzer (Yellow Springs, OH). Oxygen content was determined with a Radiometry Acid-Base laboratory (ABL-3; Copenhagen, Denmark). Myocardial uptakes of glucose and oxygen were calculated as the product of the respective A-CS differences and circumflex blood flow. Less than 1 ml of blood was required for these determinations. Serum insulin levels were determined by radioimmunoassay [25] , using a commercially available kit (Cambridge, MA). These blood samples were centrifuged at 15OOg for 10 min at 4°C and the serum was stored at -20°C for later assay. Approximately 3 ml of blood were required for the insulin determinations.
After surgical instrumentation A and CS blood samples were drawn for determination of pre-treatment myocardial substrate uptakes, and arterial blood samples were drawn for determination of pre-treatment insulin concentrations. Immediately after this, somatostatin (SRIF) infusion was begun at a rate of 0.8 pg/kg . min-' [26, 27] with concomitant infusion of insulin (10 mu/kg . min-' 1 in the presence (n = 6) or absence (n = 6) of combined beta-and alpha-adrenergic blocking agents. Saline was used in the absence of adrenergic blockade as a control. Beta-adrenergic blockade was accomplished by administration of propranolol (70 pg/kg bolus followed by 5 pug/kg. min -' infusion) [28] , and alpha-adrenergic blockade with phentolamine (95 pg/kg bolus followed by 9.5 pg/kg . min-' infusion). The adequa c of the propranolol regimen y has been tested for effective blockade of hemodynamic effects of isoproterenol and reported by us [29, 30] . The adequacy of the phentolamine regimen has been tested elsewhere [30] . The solutions of insulin, somatostatin, and adrenergic blocking agents were combined and infused i.v. at a rate of 0.2 ml/min. This was continued for 90 min after which time basal glucose uptake was determined. During this period, and for the duration of the study, arterial glucose concentrations were maintained within 5 mg/dl of the pre-treatment values to maintain hyperinsulinemic, euglycemic clamp, as previously described [11, 12, 29] .
In an earlier study [ 121, the time to loss of the biological activity of endogenous insulin was determined. In dogs that received SRIF and saline (insulin control) the time to loss of the biological activity of endogenous insulin was considered to have occurred when three consecutive glucose uptake determinations yielded similar minimal values that showed no sign of further decrease. These criteria were found to be met by 90 min after beginning SRIF infusion. Therefore, all basal readings were obtained after this time in the present study. To determine the effects of adenosine on myocardial substrate uptake intracoronary adenosine infusions (0.01 to 10 pmoles/ml saline) were administered in increasing successive logarithmic increments. All adenosine concentrations were infused into each coronary artery while the infusion of insulin/SRIF/blockade continued and euglycemic clamp was maintained. Adenosine solutions were prepared such that all infusions proceeded at a rate of 1 ml/min to each artery. Measurements of substrate uptake values were determined 30 min after initiating a particular adenosine/saline infusion rate. At the completion of each preparation, dogs were euthanized under pentobarbital anesthesia with 20 ml saturated KC1 i.v. The circumflex area of the heart (to which blood flow was being measured) was stained with monastral blue while maintaining an equal or greater pressure KC1 infusion into the LAD artery. All metabolic data were stardardized to 100 grams heart weight by dividing the substrate uptake values obtained from each dog by its circumflex perfused area weight and multiplying by 100
All data were analyzed for differences between groups and adenosine infusion rates. The values for circumflex arterial blood flow and myocardial glucose uptake required transformation by base 10 logarithm to obtain homoscedasticity prior to analyses for differences between means. Differences between means were tested using a completely randomized block design two-way analysis of variance (ANOVA), followed by least significant difference (LSD) test. Differences were considered significant when tests yielded a P value equal to or less than 0.05.
Results
Serum insulin concentrations prior to SRIF and insulin infusions were 13.6 &-3.0 and 21.2 k 3.4 @J/ml in control and adrenergic blockade groups, respectively. Exogenous insulin infusions significantly elevated serum insulin concentrations to similar levels in both groups (661 + 85 and 611 k 82 pU/ml>. Adenosine infusions had no significant effects on these concentrations.
Myocardial glucose uptake values are presented in Fig.  1 . Prior to infusion of insulin or adrenergic blocking agents (PRE), myocardial glucose uptake was not significantly different between the two groups. Insulin increased myocardial glucose uptake from 8.5 f 2.0 to 16.7 + 4.4 mg/min 100 g (PRE to BASAL, respectively; see figures) in the adrenergically intact animals (No Blockade; IZ = 6), and from 5.7 k 1.5 to 11.1 k 3.0 mg/min. 100 g in the adrenergic blockade group (n = 6). Up to 0.1 pmoles/ml of adenosine (infused at 1 ml/min) enhanced the effect of insulin, increasing the insulin-stimulated myocardial glucose uptake from 16.7 + 4.4 to 26 mg/min . 100 g in the control group, and 11 .l * 3.0 to 22.6 ? 5.8 mg/min . 100 g in the adrenergic blockade group. Insulin-stimulated myocardial glucose uptake in the control group was further increased by 1.0 ~moles/ml adenosine, and was significantly higher than in the adrenergic blockade group during 1.0 pmoles/ml adenosine infusion. At higher adenosine infusion rates, myocardial glucose uptake fell to values not significantly different from the pretreatment levels in both groups.
Mean arterial blood pressure (Table 1) was not affected during the protocol until the highest concentration of adenosine was infused (10 pmoles/ml), at which time blood pressure fell significantly in both groups. In the absence of adenosine infusions, circumflex arterial blood flow (Table 1 ) was significantly lower in the adrenergic blockade group than in the control group. Adenosine increased blood flow in a dose-dependent manner in both groups.
Heart rate ( Table 1) was decreased in the adrenergic blockade group, in agreement with previous work [29] , but neither insulin nor adenosine had any significant effect on heart rate. Myocardial oxygen uptake (MVO,; Table 1) was generally depressed by adrenergic blockade. Insulin had no significant effect on MVO,, nor did adenosine infusions. Changes in substrate utilization will vary directly with cardiac work [31, 32] . This is evident in Fig. 2 which shows a significant correlation between MVO, (index of work) and insulin-stimulated glucose uptake. Thus, at higher MVO, values insulin-stimulated glucose uptake was higher.
The glucose uptake response was again evaluated as normalized to MVO, (Fig. 3) . As expected, insulin alone increased MVO,-normalized glucose uptake from a noninsulin-dependent value of 0.36 + 0.7 to 1.2 f 0.4 and 1.3 + 0.3 mg/min . 100 g in the non-blocked and adrenergic blockade groups, respectively. Adenosine infused at 1 .O pmoles/ml increased the MVO,-normalized glucose uptake further, and had the same effect on MVO,-normalized myocardial glucose uptake in the presence or absence MVO, (ml/min~lOO g) Fig. 2 . Correlation between insulin-stimulated glucose uptake and myocardial oxygen uptake. Data were obtained from various experiments [11, 12] in which plasma insulin concentrations were between 1000 and lOOGO yU/ml.
Briefly, this was accomplished using the same methods as described in this paper, but with the infusion of various concentrations of insulin, along with sufficient glucose to maintain euglycemia, during SRIF infusion.
of adrenergic blockade (Fig. 3) . It is also noteworthy that at the highest adenosine infusion rate, glucose uptake normalized for MVO, (Fig. 3) had fallen to levels not significantly different from the baseline insulin-stimulated values, suggesting a biphasic response. To examine this question another way we compared the maximal myocardial glucose uptake values obtained during adenosine infusion relative to the values obtained with insulin alone (basal) in each animal. These data are summarized in Fig.  4 . Insulin-stimulated myocardial glucose uptake was enhanced by adenosine infusion in both groups. The absolute value of the maximal effect of adenosine in each group (left panel) was significantly elevated in both groups, compared to basal insulin effects, but was significantly lower in the adrenergic blockade group. However, when analyzed as a percentage of the respective basal insulinstimulated myocardial glucose uptake values, the maximal responses of the two groups were not different from each other (right panel). As a relative function, this comparison is independent of changing work conditions caused by the adrenergic blockade.
Discussion
Of the great volume of work concerning adenosine's actions in the heart the overwhelming majority of it has focused on vasodilatory and negative inotropic, chronotropic, and dromotropic effects [l-5] . More is now being I 21 , and that this is not an additive effect with insulin [12] . Using this preparation we demonstrated that adenosine had no effect on myocardial glucose uptake in the absence of insulin-mediated activity [12] , while in other preparations it has been suggested that insulin may not be required [23] . Also in our preparation, insulin did not increase myocardial glucose uptake when adenosine receptors are blocked pharmacologically [24] , suggesting a unique dose-dependent permissive interaction between insulin and adenosine. One of the means by which adenosine may elicit this effect is by antagonizing adrenergic effects on insulin's action. Even in isolated heart preparations this may pose a problem due to spontaneous release of catecholamines from sectioned nerve terminals. Adrenergic agents have been shown to inhibit the actions of insulin on glucose uptake in skeletal muscle, diaphragm, adipose, and myocardial tissues [13-171. Adenosine has been shown to antagonize this anti-insulin action of adrenergic agents [13-15,17,18]. The present study was conducted to determine if this might be the mechanism by which adenosine enhances insulin-stimulated myocardial glucose uptake in this preparation [l 1 ,I 21. To insure that differences were not a result of altered sensitivity to insulin, supraphysiologic doses of insulin were used to maximally stimulate this response.
The data suggest that this mechanism does not play a role in this regard. If inhibition of adrenergic effects were the primary means by which adenosine enhances insulin's action, adrenergic blockade should have had effects similar to adenosine itself on insulin-stimulated glucose uptake, and adenosine would no longer exert such effects. If this were true, we would have seen greater increases in glucose uptake with insulin alone in the adrenergically blocked group. This did not occur. Insulin-stimulated myocardial glucose uptake was slightly lower in the adrenergic blockade group, but when indexed to MVO, as a work-related parameter, was the same in both groups. Heart rate is a major determinant of myocardial work. As evidenced in Table 1 the adrenergic blockade regimen that we used caused a significant decrease in heart rate. This is probably the reason for the lower oxygen uptake values in this group, as afterload (mean arterial blood pressure) and cardiac output (data not shown) were not different between the groups. Changes in work conditions can passively alter substrate uptakes (i.e., increased work can lead to relatively proportionate increases in the uptake of each substrate [3 1,321). Some have suggested this as the reason for conflicting results reported in the literature 120,221. Thus, we examined our findings relative to MVO,. We found that adenosine increased the quantity of glucose taken up for a given MVO, (Fig. 3) . The unchanging MVO, values concomitant with adenosine-induced increases in blood flow follows from a commensurate reduction in the arterial-coronary sinus difference in oxygen content during high flows (reduced extraction). These data indicate that our findings are not merely fluctuations in glucose uptake that follow changes in cardiac work requirements. The lack of an effect of the infused adenosine on heart rate or blood pressure (except at the highest doses) is consistent with the coronary arterial infusions. These infusions were performed distal to nodal arteries that might have allowed adenosine to exert negative chronotropic effects upon infusion. Due to its rapid uptake and degradation little to no adenosine would have made it to the systemic circulation, except at the highest infusion rates which probably overwhelmed uptake and degradation pathways.
Adenosine was still able to enhance insulin-stimulated glucose uptake during adrenergic blockade. The absolute values for myocardial glucose uptake were lower than in the non-blocked group. However, the data reflecting adenosine's enhancement of insulin-stimulated glucose uptake indexed to MVO, or as a percent change from basal values demonstrate that this is an artifact of the adrenergic blockade-induced changes in cardiac work. Shanahan et al. [14] , in studying the interaction between isoproterenol and insulin in cardiac myocytes, found that isoproterenol reduced insulin-stimulated glucose uptake. When adenosine deaminase was added to the incubation medium along with isoproterenol and insulin, myocyte glucose uptake was further reduced. They interpreted this as indicating that adenosine, produced by the cells into the medium, antagonized isoproterenol's inhibitory effect on insulin. However, an alternate explanation is that adenosine was acting directly to potentiate insulin's effect. The removal of this nucleoside with adenosine deaminase may have simply negated its insulin potentiating effects. Shanahan et al. [14] did not test this by examining the effects of adenosine or adenosine deaminase on insulin's effects in the absence of beta-adrenergic stimulation.
Results from studies on the effects of adenosine on myocardial glucose metabolism in isolated perfused hearts have been disparate. Mainwaring et al. [19] demonstrated increased glucose uptake with adenosine in rat hearts. Wyatt et al. [35] found that the addition of adenosine to their perfusate increased glycolytic flux in rat hearts. In contrast, Dale et al. [20] demonstrated no effect of N6-Lphenylisopropyladenosine (an adenosine receptor agonist) on glycolysis in rat hearts. Fuller and Sugden [36] reported that addition of adenosine deaminase to rat heart perfusate increased anaerobic glycolysis and glucose uptake, implying that endogenous adenosine in their preparation was inhibiting these parameters. Others have had mixed results. Buxton et al. [21] found that adenosine infusion in rat hearts increased glucose oxidation and glycolytic flux when coronary perfusion pressure was held constant, but inhibited these when coronary perfusion pressure was allowed to fall. Finegan et al. [22] reported that addition of adenosine to their perfusate increased glucose oxidation, and decreased glycolysis, but only in the presence of palmitate in the perfusate.
Some of the disagreement in results has been attributed to varied cardiac workload conditions. Our data supports this thesis. When we normalized glucose uptake to an index of work, apparent differences in the absolute data between adrenergically blocked and non-blocked animals were abolished, and demonstrated that adenosine increased myocardial glucose uptake to similar degrees in both groups. This agrees with other reports showing that the effects of adenosine on myocardial glucose metabolism are best observed when work conditions are accounted for 1331. Some of the variance of findings regarding adenosine's metabolic effects may also be related to the effective concentrations of adenosine found in various studies. We found that adenosine enhanced glucose uptake up to an adenosine infusate concentration of 1.0 ~moles/ml; at an adenosine infusate concentration of 10 pmoles/ml glucose uptake fell to basal levels. At an average coronary blood flow of 150 ml/min during these infusions, the 1 pmole/ml infusion concentration translates to a blood concentration of < 10 PM. Many studies in isolated hearts have been performed using perfusate concentrations in excess of this (usually 100 PM). We should also remember that these adenosine infusions were added to endogenous interstitial adenosine levels to make up the effective concentration. Efficient reuptake systems [37] and rapid degradation [38] make these pre-existing adenosine levels difficult to quantify, and may vary considerably between preparations. However, effective concentrations can be identified by loss of action when blocked. Fuller and Sugden [36] reported significant decreases in isolated perfused heart flow when adenosine deaminase was added to their system, suggesting pre-existing, vasoactive concentrations of adenosine. Similarly, Finegan et al. [22] found high baseline perfusate flows that were not increased with the addition of 100 PM adenosine to the perfusate, suggesting pre-existing maximally vasodilating adenosine concentrations. In contrast, it has been reported that adenosine blockade or degradation has no effect on resting myocardial blood flow in blood perfused in situ preparations [39, 40] . We have demonstrated that adenosine receptor blockade had no effects on resting blood flow in our in situ, blood perfused cardiac preparation [24] . Based on our findings here and in previous work [ 11, 12, 24] , the response to adenosine appears to be biphasic, with stimulation of myocardial glucose uptake at lower infusion concentrations than has been used in other studies. As a result, pre-existing baseline effective concentrations of adenosine must be considered in the interpretation of any results.
Is insulin required for adenosine to have an effect on glucose metabolism? This has been a question of some controversy as well. Our previous work using the in situ dog heart preparation indicates that adenosine has no effect on myocardial glucose uptake when endogenous levels of insulin are suppressed, and importantly, when the biological activity of prior insulin exposure is allowed to wane. This may be a species-dependent phenomenon, but other explanations need to be considered. Some studies report effects of adenosine in isolated perfused rat hearts wherein no exogenous insulin is infused [ 19, [21] [22] [23] 351 . Interpretation of these results as indicating the lack of a need for insulin to elicit such responses presumes that there is no residual activity from prior exposure to endogenous insulin. However. most of these studies were reported to have been conducted within 60 min after removing the heart from the animal. Results from our lab [12] and others [26, 27] indicate that up to 90 min can be required for the biological activity of prior insulin exposure to wane. As such, isolated perfused hearts can operate with residual post-receptor insulin-induced activity for a considerable period of time in many protocols. Furthermore, because the ED,, for insulin is so low in rat and dog hearts [12, 41] even fasting levels of endogenous insulin can have profound effects on myocardial glucose metabolism. Thus, more work is needed to determine if metabolic glucose responses to adenosine require insulin in the rat heart.
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Am Beme [ 11 has reported that adenosine increases markedly during conditions of increased cardiac performance, or myocardial ischemia, reactive hyperemia, or hypoxia. Early work centered on adenosine's action on vasculature [ll, focusing on this as a classic physiological compensatory mechanism under such conditions. However, it is now apparent that adenosine may be a much more versatile molecule, exhibiting many other actions that can be advantageous. Its negative inotropic and chronotropic actions would help to reduce myocardial work requirements, and negative dromotropic effects of adenosine help to reduce the probability of ventricular fibrillation. Antagonism of adrenergic effects during periods of myocardial ischemia, when circulating catecholamines are elevated [42] , has been demonstrated to be beneficial [ 15,421. Thus, the anti-adrenergic effects of adenosine must be considered in the equation of beneficial qualities. In demonstrating its ability to increase myocardial glucose uptake another potentially beneficial role has been added to the list for adenosine, for under conditions when oxygen supply is failing to meet oxygen demand, might it not be beneficial, if only in the short term, for the uptake of substrate that can be used anaerobically to be increased?
